Our research pipeline reflects our commitment to transforming healthcare in several focus areas, Diabetes mellitus (GDD001), vaccine development (GGD002) and Cancer. Our lead program GGD002 covers in vitro and in vivo validated, of LBPs targeting diabetes. It is designed to work seamlessly in concert with the body to regulate insulin and glucose metabolism. Other preclinical-stage candidates include GGD002 for vaccine delivery and GGD003 use the body’s own immune system to target and kill cancer cells in a directed manner. Our goal is to progress these therapies through clinical trials and bring new innovative solutions from the lab to patients in a timely and safe manner not possible with more complex animal and fungi systems.